PRZOOM - /newswire/ -
Pittsburgh, PA, United States, 2015/12/23 - ChemImage Corporation was selected for $2 Million in defense funding for the further development of Eye-Safe Stand-off Fusion Detection of chemical, biological, explosive and improvised explosive device threats - ChemImage.com.
The funding for this contract comes as a part of the Fiscal Year 2010 Defense Appropriations Act that was approved by Congress and signed by the President this past weekend. Primary sponsorship for the funding came from U.S. Congressman Mike Doyle with Senate support from both Senators Arlen Specter and Bob Casey.
“We are excited for the opportunity to develop technology that has the potential to protect our troops and save lives,” said Dr. Matthew Nelson, Chief Scientist, who is Principal Investigator on the contract. “This is a real-time, on-the-move detection sensor development effort that aims to provide the capability for detection and identification of multiple threats in the presence of complex background environments.”
The system will combine multiple sensing technologies including Raman and shortwave infrared (SWIR) Chemical Imaging (i.e., hyperspectral imaging) using a sensor fusion engine developed by ChemImage. The system will help address eye-safety concerns associated with the use of lasers on the battlefield when humans are detected in the vicinity of the laser.
“The Eye-Safe project builds on demonstrated success of ChemImage standoff sensors as best-in-class for detection of hazardous materials, while addressing a critical hurdle in the successful deployment of this sensing technology”, said Dr. Patrick Treado, Founder and Chief Technology Officer at ChemImage.
ChemImage Corporation (chemimage.com) is a world leader in hyperspectral imaging technologies, provides instrumentation, software, lab services and expert consulting to government, industrial and academic organizations. ChemImage offers these products and services for a range of applications including defense, security, pharmaceuticals, forensics and biomedical diagnostic research. Our state-of-the-art hyperspectral technology can help to reveal critical chemical and biological information about processes, products and services.
ChemImage’s main headquarters is located in Pittsburgh, Pennsylvania and houses research and development laboratories as well as engineering and manufacturing facilities.